Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Centrica PLC Regulatory Filings 2019

Jul 1, 2019

5292_rns_2019-07-01_0ba665f0-a3eb-4e3b-93de-ba07032939ad.html

Regulatory Filings

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0901E

Centrica PLC

01 July 2019

1 July 2019

Centrica plc

('the Company')

Total Voting Rights

In accordance with the Disclosure and Transparency Rules ('the Rules'), we notify the market of the following:

As at 30 June 2019 the issued capital of the Company comprised 5,817,100,579 ordinary shares of 614/81 pence ('Shares'). This figure excludes 12,496,465 Shares held in treasury. All of the issued Shares carry voting rights of one vote per share.

The figure of 5,817,100,579 may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

Adam Westley

Head of Secretariat, Centrica plc

01753 494000

Centrica plc is listed on the London Stock Exchange (CNA)

Registered Office: Millstream, Maidenhead Road, Windsor, Berkshire SL4 5GD

Registered in England & Wales number: 3033654

Legal Entity Identifier number: E26EDV109X6EEPBKVH76

ISIN number: GB00B033F229

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

TVRUAVSRKRABRAR